HealthEquity Fell 11% After Raising Guidance. The Free Cash Flow Says the Panic Was the Noise

On August 27, HealthEquity did what most investors would call the right thing and got punished for it. Revenue rose 8% to $350.7 million, a touch better than analysts expected. Adjusted earnings were $1.24 a share, ahead of the $1.19 estimate. Management raised its full-year guidance. The stock fell 11.3% that day, from a $104.42 close to about $92.60.

The reason wasn't the business. It was the price people had already paid to own it. HealthEquity shares had climbed about 27% since late April and sat just beneath their 52-week high of $107.62, so by report day the market was not asking for a good quarter — it was asking for a shock. What it got was a strong quarter against a very high bar: the new full-year guidance — revenue of $1.411–$1.421 billion and adjusted EPS of $4.66–$4.73 — landed right on the roughly $4.72 the street already had in its models, and second-quarter EPS did not accelerate from the first quarter's $1.24. A stock that has to beat by more each quarter, and merely met, gets de-rated. The selloff matters less than the fact that expectations have now reset while the numbers have not broken.

To see why the "old story" was the wrong frame, you need the business model, which is simpler than the stock. HealthEquity is the largest independent custodian of health savings accounts — the tax-advantaged accounts attached to high-deductible health plans. It holds 10.7 million HSAs with roughly $38 billion of assets, and it makes money three ways: custodial income, the biggest line at about half of revenue, comes from depositing members' cash at banks and keeping the spread between what the banks pay and what HealthEquity credits members back; service revenue is account fees; interchange is card-swipe income. In the July quarter that split was $175.9 million custodial, $124.4 million service, and $50.4 million interchange.

That custodial line is where both the opportunity and the vulnerability live. It is an interest-rate business in practical terms — management's full-year model assumes an average yield on HSA cash of 3.85% to 3.90%. Everything the company has become over the last two years runs on that spread.

Which brings me to the part of this report a reader should actually hold on to: the cash-flow path. In fiscal 2026, the year that ended January 31, free cash flow reached roughly $455 million, according to the compiled financials; the trailing-twelve-month figure is about $437 million today. The machinery is cheap to run — roughly $490 million of operating cash flow against only about $54 million of capital spending. That is a free cash flow margin near 32%, and it is why a company growing revenue at a single-digit rate still prints cash as its asset base compounds: accounts up 8%, custodial assets up 14%, new account sales up 24%. Even the plain accounting says the profit is real — for every dollar of reported earnings, HealthEquity has been generating more than two dollars of operating cash flow. The July quarter's record adjusted EBITDA margin of 48%, up from 46% a year earlier, is the same story in different clothes.

Now the selloff has an actual investment meaning. Around an $8 billion market cap, HealthEquity sells for roughly 18 times trailing free cash flow, and about 20 times forward adjusted earnings using the midpoint of the raised guidance. That is not a bargain-bin price, and it would be dishonest to present it as one. It is a fair price for a compounding asset: the bull case is not that the multiple expands, but that the cash flow grows into it as the HSA asset base keeps compounding. Nothing in the July quarter contradicts that — the raised guidance adds to it.

The bear case is specific and deserves a straight answer, because the same lever that built the cash machine can unwind it. Roughly half of revenue is the custodial spread, tied to short-term rates. The free cash flow of the past two years came partly from a world where money-market yields hovered near 4%; if rates fall enough to push the average HSA cash yield below the guided 3.85%–3.90%, custodial revenue decelerates and the engine slows with it. Management flagged a second, separate friction on the call: headline price erosion in the fee-based service line as competitors press.

So set the tripwire in advance. The story holds if the HSA cash yield stays near the guided range, custodial revenue keeps compounding in high single digits or better, and adjusted EPS resumes sequential growth in the back half so fiscal 2027 lands at or above the raised $4.66–$4.73. The story is broken if the yield falls through the guide, if flat EPS becomes a pattern rather than one quarter, or if service price erosion accelerates. Those are observable. Watch them, not the ticker.

One more piece of context: even after the drop, buy-rated analysts' average target sits near $119, and the stock has since bounced about 3% to roughly $96. The market is still largely priced for the old story — a high-multiple name that has to keep clearing a rising bar. The cash-flow statement tells a cleaner one. This is not a beaten-down dog pitched as cheap; it is a quality compounder at a fair free-cash-flow multiple, and an 11% tumble on the back of a raise is one of the rare events where the market lowered its demands while the business kept improving. No DCF required — the cash-flow statement is the model. I can be wrong again; the rate lever is real. But when the market punishes a company for raising guidance, the disciplined move is to read the cash-flow statement before joining the panic.